Navitoclax for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jul 2020: Trial registered, NCT04468984
  2. 31 Aug 2020: Trial started, NCT04468984

The trials

NCT04468984: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

State
Under way
Phase
Phase 3
People
330 planned
Started
31 Aug 2020
Primary completion
29 Jan 2025
Arms
Arm C: Continued Access for Navitoclax
Results
None posted
  1. 13 Jul 2020: Trial registered
  2. 31 Aug 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.